| Literature DB >> 30689467 |
Sandrine I Samson1, Phillip S Leventhal2, Camille Salamand3, Ya Meng1, Bruce T Seet1,4, Victoria Landolfi1, David Greenberg1,5, Rosalind Hollingsworth1.
Abstract
INTRODUCTION: High-dose trivalent, inactivated, split-virus influenza vaccine (IIV3-HD) has been available in the US since 2009 for adults aged ≥ 65 years. To better understand how IIV3-HD provides improved protection against influenza, we systematically reviewed clinical studies comparing immune responses to IIV3-HD and standard-dose trivalent vaccine (IIV3-SD). AREAS COVERED: The primary objective was to determine the relative hemagglutination inhibition (HAI) antibody response of IIV3-HD vs. IIV3-SD in adults aged ≥ 65 years. Based on seven randomized studies including more than 18,500 adults aged ≥ 65 years, combined HAI geometric mean titer (GMT) ratios (95% confidence interval) approximately 1 month post-vaccination were 1.74 (1.65-1.83) for influenza A/H1N1, 1.84 (1.73-1.95) for influenza A/H3N2, and 1.47 (1.36-1.58) for influenza B. HAI GMT ratios in these studies were similar irrespective of sex, older age (≥ 75 years), frailty, and underlying conditions. Trends were similar for A/H3N2 neutralization and anti-neuraminidase antibody titers. In immunocompromised individuals, HAI GMT ratios were mostly > 1. EXPERT OPINION: In agreement with its improved efficacy and effectiveness, IIV3-HD is consistently more immunogenic than IIV3-SD in adults aged ≥ 65 years. IIV3-HD also appears more immunogenic in immunocompromised individuals.Entities:
Keywords: Elderly adults; high-dose influenza vaccine; immunocompromised; immunogenicity; systematic review
Mesh：
Substances：
Year: 2019 PMID： 30689467 DOI： 10.1080/14760584.2019.1575734
Source DB: PubMed Journal: Expert Rev Vaccines ISSN： 1476-0584 Impact factor: 5.217